Sh Akhoondzadeh, L. Kashani ,
Volume 64, Issue 5 (1 2006)
Abstract
Psychiatric disorders are common in women during their childbearing years. Special considerations are needed when psychotic disorders present during pregnancy. Early identification and treatment of psychiatric disorders in pregnancy can prevent morbidity in pregnancy and in postpartum with the concomitant risks to mother and baby. Nevertheless, diagnosis of psychiatric illnesses during pregnancy is made more difficult by the overlap between symptoms of the disorders and symptoms of pregnancy. In majority of cases both psychotherapy and pharmacotherapy should be considered. However, psychiatric disorders in pregnancy are often under treated because of concerns about potential harmful effects of medication. This paper reviews findings about the presentation and course of major psychiatric disorders during pregnancy.
Eftekhar T, Akhoondzadeh S, Ghanbari Z, Iranshahr R, Haghollahi F,
Volume 67, Issue 2 (5 2009)
Abstract
Normal
0
false
false
false
EN-GB
X-NONE
AR-SA
MicrosoftInternetExplorer4
Background: Mood
disturbances, such as anxiety, depression and psychological distress, are
common among women in menopausal period. Effect of long term estrogen
replacement on post menopausal mood
disturbances is curative but specifical studies has not done on the effects of
vaginal hormonal therapy in mood disturbances in menopause. The aim of this
study was objectives to clarify the effect extended by Hormon Replacement Therapy
(HRT) in improving post menopausal mood disturbances.
Methods: In a single
blinded clinical trial, the effects of a four months application of vaginal
esterogen (premarin) versus placebo (n=20) in each groups were evaluated on
mood status and sexual satisfaction, using the Hamilton depression score (HDS
score), and self assessment of sexual function and pleasure. Four months after
treatment completion (half applicator of nightly vaginal premarin or lubricant
vaginally) collected and analyzed with Statistical tests.
Results: Decline of
the mean HDS scores (depression score) was observed in the premarin group. The
mean HDS score (depression) after vaginal premarin decreased from (14.6±4.7) to
(3.4±2.3). (p≤0.001) also, The HDS score in placebo group increased from (10.6±3.1)
to (11±3.3), that significant difference between two groups before and after
treatment is seen. (p≤0.01). Vaginal premarin induced a greater improvement of HDS
score (p≤0.006). Mean anxiety score decreased after vaginal premarin (p≤0.000),
but is not significant difference in placebo group. (p=0.08). Sexual
Satisfaction in Vaginal premarin group is significantly higher (p≤0.001).
Conclusions: Vaginal
Estrogene directly or indirectly improved menopausal related mood and sleep
disturbances, increased and sexual satisfaction.
